Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Neuroendocrine Carcinoma Market Size Changed, over the years?
Over the recent years, the market size of neuroendocrine carcinoma has seen robust expansion. The predicted forecasted growth is from $1.63 billion in 2024 to $1.76 billion in 2025, with a compound annual growth rate (CAGR) of 7.7%. This growth momentum during the historic period is due to factors such as the growth of the imaging sector, a rise in occurrences of neuroendocrine tumors, surging investments, heightened governmental initiatives, and increased demand for treatments targeting neuroendocrine tumors.
How Much Will the Neuroendocrine Carcinoma Market Be Worth in 2029?
The market for neuroendocrine carcinoma is anticipated to experience substantial growth in the coming years, with an estimated value of $2.33 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.3%. The growth during the forecasted period can be credited to the escalating rate of cancer, an increase in product approvals, expanded use of advanced diagnostic imaging techniques, the emergence of targeted therapies, and a rise in available diagnosis and treatment methods. Key trends anticipated during this period include progressions in diagnostic technologies, enhanced imaging methods, specialized treatment strategies, developments in managing neuroendocrine tumors, and advancements in targeted therapies and immunotherapies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21229&type=smp
Which is the Largest Company in the Neuroendocrine Carcinoma Market?
Major companies operating in the neuroendocrine carcinoma market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Amgen Inc., Boehringer Ingelheim GmbH, Exelixis Inc., Lantheus Holdings Inc., HUTCHMED Limited, Dana-Farber Cancer Institute Inc., Abdera Therapeutics Inc., Orano Med S.A, Eckert & Ziegler Radiopharma GmbH, Callisto Pharmaceuticals Inc., RadioMedix Inc., Clarity Pharmaceuticals Limited, Delcath Systems Inc., Provectus Biopharmaceuticals Inc.
What Are the Main Market Drivers in the Neuroendocrine Carcinoma Industry?
The neuroendocrine carcinoma market’s expansion is projected to be spurred by the increased utilization of targeted therapies. These treatments are meticulously created to specifically target and disrupt the molecular operations or genetic modifications that lead to a disease, particularly cancer. They’re gaining popularity due to their accuracy in treating specific genetic changes, advances in personalized medicine, and improved patient outcomes with fewer side effects. Thanks to neuroendocrine carcinoma, targeted therapies can be developed which specifically target the biochemical and genetic profiles of the tumor, thereby increasing the precision and potency of the treatment. For instance, a report published by the American Society of Gene & Cell Therapy (ASGCT) and Citeline, both based in the U.S., stated that in July 2023, at the end of the first quarter, there were 247 gene therapies in Phase II. However, this number increased by 5%, reaching 260 by the end of the second quarter. Therefore, the rise of targeted therapies is fuelling the growth of the neuroendocrine carcinoma market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21229&type=smp
How Is the Neuroendocrine Carcinoma Market Segments Structured?
The neuroendocrine carcinoma market covered in this report is segmented –
1) By Type: Gastroenteropancreatic Neuroendocrine Tumors, Carcinoid Tumors, Pheochromocytoma, Medullary Thyroid Carcinoma
2) By Diagnostic Tools: Imaging, Biopsy, Serology
3) By Treatment: Chemotherapy, Radiotherapy, Surgery, Other Treatments
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Oncology Centers, Ambulatory Surgery Centers
Subsegments:
1) By Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Pancreatic Neuroendocrine Tumors (pNETs), Small Intestinal Neuroendocrine Tumors, Gastric Neuroendocrine Tumors, Colorectal Neuroendocrine Tumors
2) By Carcinoid Tumors: Pulmonary Carcinoid Tumors, Gastrointestinal Carcinoid Tumors
3) By Pheochromocytoma: Adrenal Pheochromocytoma, Extra-Adrenal Paraganglioma
4) By Medullary Thyroid Carcinoma: Sporadic Medullary Thyroid Carcinoma, Hereditary Medullary Thyroid Carcinoma (MEN2-Associated)
What Strategic Trends Are Transforming the Neuroendocrine Carcinoma Market?
Leading firms in the neuroendocrine carcinoma market are concentrating their efforts on manufacturing advanced therapeutic approaches, notably targeted radiopharmaceutical treatment, to enhance precision in treatment and patient results. This type of therapy employs radioactive molecules that can specifically single out and administer radiation to the cancer cells, thereby causing less damage to the healthy tissues. As an example, Abdera Therapeutics Inc., a biotech firm based in Canada, gained the FDA’s orphan drug designation in September 2024 for their ABD-147. This drug is aimed at treating neuroendocrine carcinoma by selectively targeting tumors that show up with the DLL3 protein, a common occurrence in more aggressive types of neuroendocrine cancers like SCLC and LCNEC. The FDA’s designation has given ABD-147 an edge in terms of opportunities for further development, tax credits for conducting clinical trials, and the potential for market exclusivity, making it a significant contender in this specific field of oncology.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/neuroendocrine-carcinoma-global-market-report
Which Global Regions Offer the Highest Growth in the Neuroendocrine Carcinoma Market?
North America was the largest region in the neuroendocrine carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroendocrine carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21229
This Report Delivers Insight On:
1. How big is the neuroendocrine carcinoma market, and how is it changing globally?
2. Who are the major companies in the neuroendocrine carcinoma market, and how are they performing?
3. What are the key opportunities and risks in the neuroendocrine carcinoma market right now?
4. Which products or customer segments are growing the most in the neuroendocrine carcinoma market?
5. What factors are helping or slowing down the growth of the neuroendocrine carcinoma market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model